Search Results - Dahkil, S

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    Abstract P1-02-07: Discordance for low and intermediate levels (1+ or 2+ by IHC) of HER2 protein expression in the phase III PRESENT trial

    Abstract P1-02-07: Discordance for low and intermediate levels (1+ or 2+ by IHC) of HER2 protein expression in the phase III PRESENT trial by Rugo, HS, Melisko, M, Ben-Baruch, NE, Price Hiller, J, Dahkil, S, Sutton, L, Mazanet, R, Mittendorf, E

    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Abstract P5-16-02: Updated efficacy, safety and translational data from MARIO-3, a phase II open-label study evaluating a novel triplet combination of eganelisib (IPI-549), atezolizumab (atezo), and nab-paclitaxel (nab-pac) as first-line (1L) therapy for locally advanced or metastatic triple-negative breast cancer (TNBC)

    Abstract P5-16-02: Updated efficacy, safety and translational data from MARIO-3, a phase II open-label study evaluating a novel triplet combination of eganelisib (IPI-549), atezoli... by Hatem, Soliman, Hargis, Jeffrey, Elias, Anthony, Lee, Arielle, Swart, Rachel, Dahkil, Shaker, Drakaki, Alexandra, Phan, Vu, Kass, Frederic, Cobleigh, Melody, Babu, Sanil, Tkaczuk, Katherine, O'Connell, Brenda, Roberts, Jennifer, Zizlsperger, Nora, Hamilton, Erika

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Editorial

    Editorial by al dahkil, Min

    Published in Psychodynamic practice
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Editorial

    Editorial by al dahkil, Min

    Published in Psychodynamic practice
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:

Search Tools: